Alpine Immune Sciences(ALPN) - 2023 Q4 - Annual Results

Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results -- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic lupus erythematosus -- SEATTLE, Washington - March 18, 2024 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinic ...